Skincare company Crown Laboratories has finalized an agreement to acquire the global, aesthetics-focused assets of medical technology company Eclipse. Company officials say the acquisition expands Crown’s aesthetics’ product portfolio and enhances Crown’s overall value as a provider of science-based aesthetic skincare solutions.
“We pride ourselves on being at the forefront of today’s aesthetics market by developing and delivering best-in-class medical technologies and products that are exceptionally safe and effective,” says Jeff Bedard, president and CEO of Crown. “This strategic acquisition furthers Crown’s mission to drive innovation and provide superior products and customer service to aesthetics providers around the world. Eclipse’s excellent products will broaden our product line and customer base, domestically and internationally.”
Paul O’Brien, CEO of Eclipse, also spoke out about the acquisition, commenting: “We are thrilled to have completed this transaction with Crown. The combination of Eclipse’s innovative product offerings with Crown’s leadership position in the aesthetics market will undoubtedly expand the reach and optimize the range of services healthcare professionals can provide to their patients.”
As a company focused on skincare, Crown will integrate the Eclipse products into the Aesthetics business unit of Crown to complement its SkinPen® Precision and other brands.